0.2276  -0.004 (-1.64%)		07-14 16:00
Open: 0.2314 High: 0.2367 Volume: 1,303,113		Pre. Close: 0.2314 Low: 0.22 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.35	1-year :	0.42
Resists	First :	0.3	Second :	0.36
Pivot price	0.24
Supports	First :	0.21	Second :	0.18
MAs	MA(5) :	0.23	MA(20) :	0.25
	MA(100) :	0.29	MA(250) :	0.47
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	26.6	D(3) :	27.1
RSI	RSI(14): 37.5
52-week	High :	12	Low :	0.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AZTR ] has closed above bottom band by 8.0%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.24 - 0.24	0.24 - 0.24
Low:	0.22 - 0.22	0.22 - 0.22
Close:	0.22 - 0.23	0.23 - 0.23

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Thu, 03 Jul 2025
Azitra Inc Approves Increase in Common Stock Shares - TipRanks

Wed, 18 Jun 2025
Azitra Inc Plans Stock Increase at Annual Meeting - TipRanks

Tue, 17 Jun 2025
Azitra Inc Announces Positive Phase 1b Trial Results - TipRanks

Tue, 17 Jun 2025
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PR Newswire

Tue, 13 May 2025
Azitra Advances Novel Skin Disease Treatments: Key Trial Results Expected in 2025 - Stock Titan

Thu, 24 Apr 2025
$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	8 (M)
Held by Insiders	6.83e+006 (%)
Held by Institutions	10.6 (%)
Shares Short	311 (K)
Shares Short P.Month	0 (K)

EPS	-1.012e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-35 %
Return on Assets (ttm)	470.3 %
Return on Equity (ttm)	-93.5 %
Qtrly Rev. Growth	408200 %
Gross Profit (p.s.)	0.02
Sales Per Share	0.05
EBITDA (p.s.)	-0.63
Qtrly Earnings Growth	92.3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	4.39
Price to Cash Flow	0

Dividend	0
Forward Dividend	208380
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.